Interference with association of K-Ras4B with the plasma membrane either via inhibition of prenylation or via competition for membrane binding sites with small molecules abrogates signaling and has been extensively used to develop anti-cancer therapeutics [8]. The gene discussed is KRAS; the disease is cancer.